CV Sciences (CV Sciences) Retained Earnings : $-84.59 Mil (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is CV Sciences Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. CV Sciences's retained earnings for the quarter that ended in Dec. 2023 was $-84.59 Mil.

CV Sciences's quarterly retained earnings declined from Jun. 2023 ($-83.27 Mil) to Sep. 2023 ($-83.72 Mil) and declined from Sep. 2023 ($-83.72 Mil) to Dec. 2023 ($-84.59 Mil).

CV Sciences's annual retained earnings declined from Dec. 2021 ($-79.48 Mil) to Dec. 2022 ($-87.69 Mil) but then increased from Dec. 2022 ($-87.69 Mil) to Dec. 2023 ($-84.59 Mil).

CV Sciences Retained Earnings Historical Data

The historical data trend for CV Sciences's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CV Sciences Retained Earnings Chart

CV Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-41.64

-63.92

-79.48

-87.69

-84.59

CV Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings	Get a 7-Day Free Trial															-87.69	-81.98	-83.27	-83.72	-84.59

CV Sciences Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

CV Sciences (OTCPK:CVSI) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

CV Sciences (CV Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CV Sciences Inc (OTCPK:CVSI) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

9530 Padgett Street, Suite 107, San Diego, CA, USA, 92126

Website

https://www.cvsciences.com

CV Sciences Inc is a consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, which are sold through a range of sales channels from business-to-business (B2B) to business-to-consumer (B2C). The company also operates a drug development program focused on developing and commercializing cannabidiol (CBD)-based novel therapeutics.

Executives

William Mccorkle	director	10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Corroon James Michael Jr.	director	9530 PADGETT STREET, SUITE 107, SAN DIEGO CA 92126
Maroon Joseph C Md	director	2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Mona Michael Joseph Jr	director	2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Paul Blake	director	145 BRANDYWINE PKWY, WEST CHESTER PA 19380
Douglas Jesse Mackay	officer: Sr VP Scientific/Regulatory	10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Joseph D Dowling	officer: Chief Financial Officer	2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Joerg Grasser	officer: CFO	2688 SOUTH RAINBOW BLVD STE B, LAS VEGAS NV 89146
Elizabeth Ann Altman	director	10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Terri F Graham	director	C/O JACK IN THE BOX INC, 9330 BALVOA AVE, SAN DIEGO CA 92123
Stephen Martin Schmitz	director	2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Gary Sligar	director	2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
James A Mcnulty	director	C/O CV SCIENCES, INC., 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Larry Phillip Raskin	director	1630 FUNNY CIDE DRIVE, WAXHAW NC 28173
Mackay Ventures Inc.	other: Member 10% holding group	6325 S. JONES BOULEVARD #500, LAS VEGAS NV 89118